Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term peripheral-blood. Found 14 abstracts

Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 2014 Mar;111(9):3514-9.   PMCID: PMC 3948254
Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect (TM) versus Veridex CellSearch (TM) system. International journal of cancer. 2012 Apr;130(7):1590-7.   PMCID: *
De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer. 2012 Aug;12(4):264-9.   PMCID: not NIH funded
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology. 2012 May;23(5):1144-50.   PMCID: *
Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer. British Journal of Cancer. 2012 Oct;107(8):1286-94.
Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer. British Journal of Cancer. 2012 Oct;107(8):1286-94.   PMCID: PMC3494437
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment. 2011 Sep;129(2):451-8.   PMCID: *
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011 Jun;13(3):R67.   PMCID: PMC3218956
Mego M, De Giorgi U, Dawood S, Wang XM, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International journal of cancer. 2011 Jul;129(2):417-23.   PMCID: not NIH funded
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology. 2011 Jun;29(18):2598-607.   PMCID: not NIH funded
Negin BP, Cohen SJ. Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges. Current treatment options in oncology. 2010 Jun;11(1-2):1-13.   PMCID: not NIH funded
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The oncologist. 2009 Jan;14(11):1070-82.   PMCID: not NIH funded
Kotz KW, Schilder RJ. High-Dose Chemotherapy and Hematopoietic Progenitor-Cell Support for Patients with Epithelial Ovarian-Cancer. Seminars in Oncology. 1995 Jun;22(3):250-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term peripheral-blood

peripheral-blood survival therapy breast-cancer chemotherapy expression trial system progression Circulating tumor cells progression-free epithelial-cells identification ep-cam clinical-significance carcinoma healthy-subjects circulating tumour cells (CTC) renal cancer-circulating endothelial cells (CEC)-M30-sunitinib prognostic value disease endothelial-cells carcinomas of-life measure mammalian target therapeutic target marrow cells Prognostic markers prostate-specific antigen resistance ovarian solid biomarker bone metastases bone-marrow transplantation randomized trial epithelial-mesenchymal transition platinum-resistant t-cell lymphoma network colony-stimulating factor her2 status prognostic factor circulating tumor cells-breast cancer liquid biopsy blood cell biomarkers combination progenitors tumors Prognostic factors CT refractory risk Breast cancer resistant metastatic breast cancer predict survival Prognosis Ovarian clinical trial resistant prostate-cancer Circulating tumor cells Bone metastases-Lymphocytopenia-Metastatic breast cancer-PET PI3K pathway HER2 circulating tumor cells-immunohistochemical subtypes-metastatic breast cancer-tumor markers cancer gene cancer screening bevacizumab gynecologic-oncology-group colorectal-cancer disease progression t-cells solid tumors bone-marrow markers Prostate cancer mTOR Metastatic breast cancer circulating tumor cells phase-iii trial messenger-rna diagnosis 2010 orgoulias v-j clin oncol-v28-ps15 classification HER2 cyclophosphamide rt-pcr regression carcinoma patients lineage carboplatin yield predictive markers phase metastatic breast-cancer molecular-detection estrogen-receptor Colon cancer metastasis polymerase-chain-reaction cancer metastasis phase-i-ii migration prognostic factors carcinoma-cells prostate-cancer AKT lymphomas megakaryocytes evolving technology intensity analysis 1st-line treatment inhibitor amplification immunomagnetic enrichment lymphopenia predicting recurrence Artificial neural metastatic colorectal-cancer
Last updated on Monday, May 04, 2020